Jbio

Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference